Drug – bio-affecting and body treating compositions – Effervescent or pressurized fluid containing – Organic pressurized fluid
Reexamination Certificate
2007-05-08
2007-05-08
Padmanabhan, Sreeni (Department: 1616)
Drug, bio-affecting and body treating compositions
Effervescent or pressurized fluid containing
Organic pressurized fluid
C514S210030, C514S210150, C514S837000, C514S924000, C514S932000, C514S933000, C514S951000, C540S200000, C540S355000, C424S489000
Reexamination Certificate
active
10613639
ABSTRACT:
A method and a composition for treatment of pulmonary bacterial infections caused by gram-negative bacteria suitable for treatment of infection caused byEscherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacterspecies,Serratia marcescensas well as those caused byBurkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans,and multidrug resistantPseudomonas aeruginosa,using a concentrated formulation of aztreonam lysinate delivered as an aerosol or dry powder formulation.
REFERENCES:
patent: 4550105 (1985-10-01), Matsuo et al.
patent: 4572801 (1986-02-01), Matsuo et al.
patent: 4610824 (1986-09-01), Trüner
patent: 4673739 (1987-06-01), Matsuo et al.
patent: 4775670 (1988-10-01), Sykes et al.
patent: 4822788 (1989-04-01), Kishimoto et al.
patent: 4826973 (1989-05-01), Anderson et al.
patent: 4888998 (1989-12-01), Buzza et al.
patent: 4946838 (1990-08-01), Floyd et al.
patent: 5875776 (1999-03-01), Vaghefi
patent: 5994340 (1999-11-01), Maiti et al.
patent: 6054431 (2000-04-01), Horwitz et al.
patent: 6303103 (2001-10-01), Akehurst et al.
patent: 6518239 (2003-02-01), Kuo et al.
patent: 2004/0009126 (2004-01-01), Pilkiewicz
patent: 0297580 (1989-01-01), None
patent: 0297580 (1989-01-01), None
patent: 0297580 (1989-01-01), None
patent: 0297580 (1990-01-01), None
patent: 0297580 (1999-01-01), None
patent: WO 0134232 (2001-05-01), None
Bastin, R. J. et al. “Salt Selection and Optimisation Procedures for Pharmaceutical New Chemical Entities” Org. Proc. Res. & Develop. 2000, 4, 427-435.
Purification of Laboratory Chemicals (PLC), 4th Edn., Elsevier: 1996, Chapter 1.
Dietzsch, H.-J et al. Pediatrics 1975, 55(1), 96-100.
John A. Bosso, et al., Efficacy of Aztreonam in Pulmonary Exacerbations of Cystic Fibrosis,The Pediatr. Infect. Dis. J., 6:393-397 (1987).
James L. Cook, M.D., Gram-Negative Bacillary Pneumonia in the Nosocomial Setting,The American Journal of Medicine,, 88:3C-34S-37S.
A. Boccazzi, et al., The Pharmacokinetics of Aztreonam and Penetration into the Bronchial Secretions of Critically Ill Patients,Journal of Antimicrobial Chemotherapy, 23:401-407 (1989).
Harold C. Neu, M.D., Aztreonam Activity, Pharmacology and Clinical Uses,The American Journal of Medicine, 88:3C-2S-3C-6S.
John J. LiPuma, MD,Burkholderia cepacia, Management Issues and New Insights,Clinics in Chest Medicine, 19/3:473-486 (Sep. 1998).
Stephen C. Aronoff, et al., In Vitro Activities of Aztreonam, Piperacillin, and Ticarcillin Combined with Amikacin Against Amikacin-ResistantPseudomonas aeruginosaandP. cepaciaIsolates from Children with Cystic Fibrosis,Antimicrobial Agents and Chemotherapy, 25/2:279-280 (Feb. 1984).
John A. Bosso, et al., In Vitro Activities of Combinations of Aztreonam, Ciprofloxacin and Ceftazidime Against Clinical Isolates ofPseudomonas aeruginosaandPseudomonas cepaciafrom Patients with Cystic Fibrosis,Antimicrobial Agents and Chemotherapy, 34/3:487-488 (Mar. 1990).
John M. Matssen, et al., The Use of Aztreonam in the Cystic Fibrosis Patient,Pediatr. Infect. Dis. J., 8/9:S117-S119 (1989).
Preston W. Campbell III, MD., et al., Use of Aerosolized Antibiotics in Patients with Cystic Fibrosis, Consensus Conference, pp. 775-789 (Sep. 1999).
Dapena Fernandez J., et al., Inhaled Aztreonam Therapy in Patients with Cystic Fibrosis Colonized withPseudomonas aeruginosa, Spanish Annals on Pediatrics, 40/3 (1994).
Gerald C. Smaldone, et al., Aerosolized Antibiotics: Current and Future,Respiratory Care, 45/6:667-675 (Jun. 2000).
Thomas G. O'Riordan, MD, Inhaled Antimicrobial Therapy: From Cystic Fibrosis to the Flue,Respiratory Care, 45/7:836-845 (Jul. 2000).
Robert G. Bell, et al., Stability of Intravenous Admixtures of Aztreonam and Cefoxitin, Gentamicin, Metronidazole, or Tobramycin,American Journal of Hospital Pharmacy, 43:1444-1453 (Jun. 1986).
Michael J. James, et al, Stability of Intravenous Admixtures of Aztreonam and Ampicillin,American Journal of Hospital Pharmacy, 42:1095-1100 (May 1985).
Desppina Daisy Frangolias, et al.,Burkkholderia cepaciain Cystic Fibrosis,Am J of Respir Crit Care Med., 160:1572-1577 (1999).
Diane H. Johnson, et al., Aztreonam, Medical of Clinics of North America, 79/4:733-743 (Jul. 4, 1995).
Woo, M.S., et al., Use of Aerosolized Aztreonam in CF Lung Transplant Patients Colonized WithBurkholder cepacia, 2002 Cystic Fibrosis Conference, p. 322:419.
Petra Borsje, MD, et al., Aerosol Therapy in Cysitc Fibrosis: A Survey of 54 CF Centers,Pediatric Pulmonology, 30:368-376 (2000).
Rafael Canton, PD, PhD, et al., Lung Colonization withEnterobacteriaceaeProducing Extended-Spectrum β-Lactamases in Cystic Fibrosis Patients,Pediatric Pulmonology, 24:213-217 (1997).
S. Ballestero, et al.,Stenotraphomonas maltophiliain Cystic Fibrosis Patients, 20thEuropean Cystic Conference, Brussels, Belgium, pp. 18-21 (Jun. 1995).
Sira Carrasco, et al., The General Approach to Cystic Fibrosis Pulmonary Infection in Spain,Cystic Fibrosis Pulmonary Infections: Lessons From Around The World, Chapter 18, pp. 223-230 (1996).
Klaus Florey, Aztrenonam,Analytical Profiles of Drug Substances, 17:1-39 (1988).
Ajit B. Thakur, et al., Interaction of Metronidazole with Antibiotics Containing the 2-Aminothiazole Moiety,Pharmaceutical Research, 8/11:1424-1429 (1991).
S. A. Ranadive, et al., Formation, Isolation and Identification of Oligomers of Aztreonam,European Journal of Pharmaceutical Sciences, 3:281-291 (1995).
Brian E. Scully, M.B., et al., Use of Aztreonam in the Treatment of Serious Infections Due to Multiresistant Gram-Negative Organisms IncludingPseudomonas aeruginosa, The American Journal of Medicine, 78:251-261 (Feb. 1995).
Hiram C. Polk, Jr. MD, et al., Treatment of Pneumonia in Mechanically Ventilated Trauma Patients,Arch Surg, 132:1086-1092 (Oct. 1997).
Stephen P. Newman, Ph.D., Aerosol Deposition Considerations in Inhalation Therapy,Chest, 88:2, 152S-160S (Aug. 1995).
Gerald C. Smaldone, et al., Aerosolized Antibiotics: Current and Future,Respiratory Care, 45/6:667-675 (Jun. 2000).
Thomas G. O'Riordan, MD, Inhaled Antimicrobial Thereapy: From Cystic Fibrosis to the Flu,Respiratory Care, 45/7:836-845 (Jul. 2000).
Robert G. Bell, et al., Stability of Intravenous Admixtures of Aztreonam and Cefoxitin, Gentamicin, Metronidazole, or Tobramycin,American Journal of Hospital Pharmacy, 43:1444-1453 (Jun. 1986).
Michael J. James, et al., Stability of Intravenous Admixtures of Aztreonam and Ampicillin,American Journal of Hospital Pharmacy, 42:1095-1100 (May 1985).
Alstrum-Acevedo James H.
Corus Pharma, Inc.
Padmanabhan Sreeni
Peters Verny LLP
Verny Hana
LandOfFree
Inhalable aztreonam lysinate formulation for treatment and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhalable aztreonam lysinate formulation for treatment and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhalable aztreonam lysinate formulation for treatment and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3778395